Experienced in Progressive Multifocal Leukoencephalopathy

Dr. Gavin P. Dunn

Neurosurgery

Mass General Brigham

Massachusetts General Physicians Organization Inc

55 Fruit St,

Boston, MA

Clinical Trials:Currently Recruiting for 2 Trials

Accepting New Patients

Offers Telehealth

Experienced in Progressive Multifocal Leukoencephalopathy

Mass General Brigham

Massachusetts General Physicians Organization Inc

55 Fruit St,

Boston, MA

OverviewInsuranceLocationsClinical Research

Overview

Gavin Dunn is a Neurosurgery provider in Boston, Massachusetts. Dr. Dunn is rated as an Experienced provider by MediFind in the treatment of Progressive Multifocal Leukoencephalopathy. His top areas of expertise are Astrocytoma, Glioblastoma, Glioma, Awake Craniotomy, and Gamma Knife Radiosurgery. Dr. Dunn is currently accepting new patients.

His clinical research consists of co-authoring 128 peer reviewed articles and participating in 15 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties

Neurosurgery

Licenses

Neurological Surgery in MO

Hospital Affiliations

Massachusetts General Hospital

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance

Find your insuranceClose

Accepted insurance plans:

Anthem

Humana

HMO
INDEMNITY
POS
PPO

Medicaid

OTHER MEDICAID
STATE MEDICAID

Locations

MASSACHUSETTS GENERAL PHYSICIANS ORGANIZATION INC
55 Fruit St, Boston, MA 02114

Call: 617-724-0287

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

15 Clinical Trials

Phase II Trial of SMO/ AKT/ NF2/CDK Inhibitors in Progressive Meningiomas With SMO/ AKT/ NF2/CDK Pathway Mutations

Enrollment Status: Recruiting

Publish Date: October 08, 2025

Intervention Type: Drug

Study Drugs: Vismodegib, GSK2256098, Capivasertib, Abemaciclib

Study Phase: Phase 2

A Pilot Study to Assess the Safety, Feasibility, and Preliminary Efficacy of a Neoepitope-based Personalized DNA Vaccine Approach in Pediatric Patients With Recurrent Brain Tumors

Enrollment Status: Recruiting

Publish Date: June 29, 2025

Intervention Type: Device, Biological, Procedure

Study Drug: Personalized neoantigen DNA vaccine

Study Phase: Phase 1

A Phase II Study of Checkpoint Blockade Immunotherapy in Patients With Somatically Hypermutated Recurrent WHO Grade 4 Glioma

Enrollment Status: Active_not_recruiting

Publish Date: September 09, 2025

Intervention Type: Procedure, Biological

Study Drugs: Ipilimumab, Nivolumab

Study Phase: Phase 2

A Phase I/II Study Testing the Safety, Toxicities, and Efficacy of MK-3475 in Combination With MRI-guided Laser Ablation in Recurrent Malignant Gliomas

Enrollment Status: Completed

Publish Date: May 29, 2025

Intervention Type: Biological, Device

Study Drug: Pembrolizumab

Study Phase: Phase 1/Phase 2

A Phase I/II Dose-escalation and Dose-expansion Study of Disulfiram/Copper With Concurrent Radiation Therapy and Temozolomide in Patients With Newly Diagnosed Glioblastoma

Enrollment Status: Completed

Publish Date: April 10, 2025

Intervention Type: Drug, Procedure, Radiation

Study Drugs: Disulfiram, Copper Gluconate, Temozolomide

Study Phase: Phase 1/Phase 2

Immunotherapy With MK-3475 in Locoregionally Advanced, Surgically Resectable Head and Neck Squamous Cell Carcinoma

Enrollment Status: Active_not_recruiting

Publish Date: January 14, 2025

Intervention Type: Radiation, Procedure, Biological, Drug

Study Drugs: Pembrolizumab, Cisplatin

Study Phase: Phase 2

A Pilot Study to Assess the Safety, Feasibility, and Immunogenicity of a Neoantigen-based Personalized in Patients With Newly Diagnosed, Unmethylated Glioblastoma

Enrollment Status: Active_not_recruiting

Publish Date: January 10, 2025

Intervention Type: Device, Biological, Drug

Study Drugs: Personalized neoantigen DNA vaccine, Plasmid encoded IL-12

Study Phase: Phase 1

A Pilot Study of Using MRI-Guided Laser Heat Ablation to Induce Disruption of the Peritumoral Blood Brain Barrier to Enhance Delivery and Efficacy of Treatment of Pediatric Brain Tumors

Enrollment Status: Terminated

Publish Date: November 01, 2024

Intervention Type: Drug, Device

Study Drugs: Doxorubicin, Etoposide

Study Phase: Phase 2

Mapping Draining Lymph Nodes in CNS Malignancies

Enrollment Status: Terminated

Publish Date: December 21, 2023

Intervention Type: Drug

Study Drug: Tc-99m tilmanocept

Study Phase: Phase 1

A Phase Ib Study of Neoadjuvant Avelumab and Hypofractionated Proton Radiation Therapy Followed by Surgery for Recurrent Radiation-refractory Meningioma

Enrollment Status: Terminated

Publish Date: June 15, 2023

Intervention Type: Radiation, Drug, Procedure

Study Drug: Avelumab

Study Phase: Phase 1

A Phase IB Study to Use Tadalafil to Overcome Immunosuppression During Chemoradiotherapy for IDH-wildtype Grade III-IV Astrocytoma

Enrollment Status: Completed

Publish Date: June 13, 2023

Intervention Type: Drug

Study Drug: Tadalafil

Study Phase: Phase 1

A Pilot Study to Assess the Safety, Feasibility, and Immunogenicity of a Neoantigen-based Personalized Vaccine Combined With Immune Checkpoint Blockade Therapy in Patients With Newly Diagnosed, Unmethylated Glioblastoma

Enrollment Status: Terminated

Publish Date: October 27, 2021

Intervention Type: Procedure, Biological

Study Phase: Phase 1

A Pilot Study of Using MRI-Guided Laser Heat Ablation to Induce Disruption of the Peritumoral Blood Brain Barrier to Enhance Delivery and Efficacy of Doxorubicin in the Treatment of Recurrent Glioblastoma Multiforme

Enrollment Status: Completed

Publish Date: August 27, 2021

Intervention Type: Device, Drug, Other

Study Phase: Phase 1

A Phase II Study of MEDI4736 (Durvalumab) in Patients With Brain Metastasis From Epithelial-derived Tumors

Enrollment Status: Terminated

Publish Date: November 06, 2018

Intervention Type: Drug

Study Phase: Phase 2

A Pilot Study to Assess the Safety, Feasibility, and Preliminary Efficacy of a Neoepitope-based Personalized Vaccine Approach in Patients With Newly Diagnosed Glioblastoma

Enrollment Status: Terminated

Publish Date: November 17, 2017

Intervention Type: Drug, Biological

Study Phase: Phase 1

View 13 Less Clinical Trials

128 Total Publications

Immunologic specificity in glioblastoma: Antigen discovery and translational implications.

Journal: Neuro-oncology advances

Published: September 11, 2025

View All 128 Publications

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Dunn's expertise for a condition

ConditionClose